Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical skin and soft tissue 17 infection that is associated with disability and social stigma. The mainstay of BU treatment is an 18 eight-week course of 10 mg/kg rifampin (RIF) and 150 mg/kg streptomycin (STR). Recently, the 19 injectable STR has been shown to be replaceable with oral clarithromycin (CLR) for smaller 20 lesions for the last four weeks of treatment. A shorter, all-oral, highly efficient regimen for BU is 21 needed, as the long treatment duration and indirect costs currently burden patients and health 22 based on higher rifamycin doses that are currently being evaluated against tuberculosis in clinical 32 trials could shorten and improve therapy of Buruli ulcer. 33 34 Words: 250/250 35
systems. Increasing the dose of RIF or replacing it with the more potent rifamycin drug 23 rifapentine (RPT) could provide such a regimen. Here, we performed a dose-ranging experiment 24 of RIF and RPT in combination with CLR over four weeks of treatment in a mouse model of M. 25 ulcerans disease. A clear dose-dependent effect of RIF on both clinical and microbiological 26 outcomes was found, with no ceiling effect observed with tested doses up to 40 mg/kg. containing regimens were more effective on M. ulcerans. All RPT-containing regimens achieved 28 culture negativity after only four weeks while only the regimen with the highest RIF dose (40 29 mg/kg) did so. We conclude that there is dose-dependent efficacy of both RIF and RPT and that 30 a ceiling effect is not reached with the current standard regimen used in the clinic. A regimen 31
Introduction 36 37 Buruli ulcer (BU) is a neglected tropical disease caused by Mycobacterium ulcerans. This 38 pathogen is phylogenetically related to M. tuberculosis and M. leprae and is believed to have 39 evolved from a common ancestor, M. marinum (1). BU presents as skin and soft tissue lesions, 40 potentially leading to scarring, contracture, physical impairment and psychosocial exclusion of 41 patients due to disfiguring wounds (2). In 2015, BU was reported from 33 countries mainly in 42 sub-Saharan West Africa, where it predominantly occurs in rural communities (3). BU treatment 43 formerly consisted of wide surgical excision and skin grafting (4). Following a phase of 44 antibiotic regimen discovery and development in a murine model of BU and a subsequent 45 clinical trial, the World Health Organization (WHO) recommended treatment with rifampin 46 (RIF) 10 mg/kg body weight orally and streptomycin (STR) 15 mg/kg by intramuscular 47 injection, both administered daily for 8 weeks. Despite good clinical outcomes with this regimen 48 (5, 6), injectable streptomycin causes ototoxicity in 25-30% of patients, nephrotoxicity and risk 49 of infection by contaminated needles (7) . Streptomycin can be replaced by clarithromycin 50 (CLR), which has a largely bacteriostatic effect on M. ulcerans, for the last four weeks of the 51 eight-week regimen for early, limited lesions (8). An ongoing trial (ClinicalTrials.gov Identifier: 52 NCT01659437) is investigating an all-oral eight-week RIF+CLR regimen with the standard dose 53 of RIF 10 mg/kg. Still, despite free treatment in most countries, the indirect costs of 54 hospitalization and loss of income burden patients and families (9, 10). A shortened, highly 55 effective, all-oral regimen, is urgently needed to improve care for this neglected tropical disease. 56 57 4
Rifampin is a rifamycin antibiotic and the mainstay oral drug in treatment of M. ulcerans. The 58 currently recommended dose of 10 mg/kg has been adopted from regimens to treat tuberculosis 59 (TB), where this dose was chosen mainly for economic reasons and in fear of toxicity associated 60 with high-dose intermittent regimens when the drug was first introduced in the 1970's (11). 61
Recently, interest in using higher doses of RIF as a means to shorten the duration of treatment for 62 TB has intensified. Trials have demonstrated that treatment with up to 35 mg/kg RIF appears to 63 be safe and offers a nonlinear increase in exposure to the drug that is associated with more rapid 64 sputum culture conversion (12, 13) . Further studies showed that high-dose RIF-containing 65 regimens improve and shorten the duration of TB therapy (14-16). Rifapentine (RPT) is another 66 rifamycin antibiotic that is active against M. tuberculosis and M. ulcerans. It is slightly more 67 active in vitro against M. ulcerans, with an MIC of 0.125 µg/ml compared to RIF (0.25 µg/ml) 68 and is effective in vivo in mice at a daily dose of 10 mg/kg (17). Its longer half-life also makes it 69 an attractive alternative to RIF. Higher daily doses of RPT are more active in murine models of 70 TB (18). Furthermore, RPT doses up to 20 mg/kg were safe in humans (19) and shown to 71 increase the rate of sputum culture conversion in TB patients in an exposure-dependent manner 72 that may lead to shorter treatment durations for TB (20, 21) . In Buruli ulcer, a regimen of RPT at 73 10 mg/kg/day plus CLR was shown to be more effective than RIF+STR in a mice (22) . Also, 74 combining RIF at 10 to 40 mg/kg/day with clofazimine were shown to reduce treatment duration 75 in the Buruli ulcer footpad model, recently (23). We hypothesize that regimens containing high-76 dose RIF or RPT will be a next pivotal step in improving Buruli ulcer chemotherapy by 77 increasing efficacy and reducing duration. To evaluate an all-oral regimen with high-dose RIF or RPT in combination with the standard 80 macrolide used today, CLR, we performed dose-ranging experiments with escalating doses of 81 both drugs in combination with CLR in the mouse footpad model of BU. We identified high-82
dose rifamycin-containing regimens that are more bactericidal than the same all-oral regimen 83 with RIF at the standard dose. These regimens can be evaluated in clinical trials in hopes of 84 unburdening patients from long-term treatment, reducing indirect costs and improving 85 adherence. RIF and STR were purchased from Sigma (St. Louis, MO, USA). RPT and CLR were kindly 105 provided by Sanofi (Bridgewater, NJ, USA) and Abbott (Abbott Park, IL, USA), respectively. 106 RIF, RPT and STR were dissolved in distilled water, while CLR was suspended in distilled water 107 with 0.05% agarose. The doses for RIF were 5, 10, 20, and 40 mg/kg; the doses for RPT were 5, 108 10, and 20 mg/kg; the dose for STR was 150 mg/kg, and the dose for CLR was 100 mg/kg. The 109 7 doses for the rifamycins produce exposures similar to the average plasma AUC observed in 110 humans at doses up to 35 mg/kg for RIF and 20 mg/kg for RPT (16, 26) . The doses for STR and 111 CLR produce plasma AUC values similar to human doses of 15 mg/kg and 7.5 mg/kg, 112
respectively (27) (28) (29) (30) . 113 114
Infection and treatment 115
Female BALB/c mice (n=110), aged 4-6 weeks were purchased from Charles River 116 (Wilmington, MA, USA) and allowed to acclimatize for 5 days upon arrival at the facility. Food 117 and water were provided ad libitum. Mice were infected with approximately 4.56 log 10 CFU of 118 Mu1059AL in 0.03 ml PBS into both hind footpads via subcutaneous injection. Five untreated 119 mice were sacrificed the following day to confirm the number of implanted CFU. Animals were 120 regularly checked for signs of general illness and progression of footpad infection. The swelling 121 grade was used to evaluate M. ulcerans-induced footpad pathology, as previously described (29). 122
A swelling grade of 0 corresponds to a normal footpad, grade 1 to a non-inflammatory but 123 swollen footpad, grade 2 to inflammatory swelling with edema and redness and 3 swelling of the 124 entire hind-foot. At week 6 post-infection (day 0), animals were randomized into treatment 125 groups and treatment was initiated. Drugs were administered once daily, 5 days per week. STR 126 was administered by subcutaneous injection. All other drugs were administered in 0.2 ml via 127 esophageal gavage. Sacrifices for CFU counts were always performed three days after the last 128 dose of antibiotic was administered to minimize drug carryover effect. 129 130 Treatment outcome monitoring 131
After treatment commenced, the swelling grade and relative light units (RLU) emitted from 132 autoluminescent bacteria in the footpads were measured weekly, as previously described (25), 133 while mice were anesthetized via intraperitoneal injection of ketamine/xylazine 87.5/12.5 mg/kg 134 (Zoetis, Kalamazoo, MI). At day 0, week 2 and week 4, 5 mice per group were sacrificed to 135 assess CFU counts. Mouse footpad tissue was carefully harvested from both hind footpads with 136 the exception of the well-defined control groups R10, R10C100 and R10C150 where only one 137 footpad was analyzed per mouse. Tissue was finely minced with scissors before being suspended 138 in 2.0 ml PBS. The suspensions were vortexed for homogenization and quantitative bacterial 139 cultures were performed as described above. Half of the footpad homogenate was plated and the 140 lower limit of detection was 2 CFU/footpad. 141 142 Data analysis 143 CFU counts were log-transformed. To compare mean CFU between treatment groups, student's 144 t-test and analysis of variance (ANOVA) were used. The value of α was set at 0.05. Data were 145 analyzed and graphs were computed using GraphPad Prism version 7.0a (GraphPad Software, 146
Inc., San Diego, CA). 147
Results 148 149 Infection 150
Successful implantation of viable bacteria was confirmed by a mean (±SD) footpad CFU count 151 of 4.09 log 10 (± 0.23) CFU on the day after infection. In untreated animals, clinical pathology, as 152 assessed by swelling grade, stayed at a level of 2 during the first two weeks of the treatment 153 phase and improved to 1.25 in week 4 (Fig 1) . RLU also declined over time in untreated mice, 154 however less so than in treated animals (Fig 2) . 155 156
Response to treatment 157
Other than C100, all treatment regimens reduced the number of RLU measured from footpads. 158 R5C100 and R10 were somewhat less effective than the other combination treatments which all 159 had very similar effects on RLU counts. The swelling grade, however was affected in a more 160 dose-dependent manner. At week 2, median swelling of untreated mice was 2 and CFU log 10 161 6.31 (± 0.31). The positive control regimen R10S150 led to rapid clinical improvement as shown 162 by decreased swelling grade (median 0.5), which is in agreement with previous studies (31). 163
Monotherapy with CLR100 performed worst in all parameters, as expected. All test regimens 164 resulted in a statistically significant (p<0.0015 -0.0001) reduction in CFU by week 2, compared 165 to untreated mice, except RIF10 and R5C100 (Fig 3, Table S1 ). Animals treated with C100 and 166 P5 were not sacrificed for CFU evaluation at week 2. RIF-containing combination regimens 167 efficiently reduced footpad CFU counts by week 2 in a dose dependent fashion (Fig 3) . RPT-168 containing regimens had a larger effect in terms of swelling grade and CFU reduction than RIF-169 containing regimens (Fig 3) . All groups receiving rifapentine or rifampin at ≥ 20 mg/kg had 170 mean CFU counts as low or lower than the rifampin-streptomycin control. Although no dose-171 response effect was observed for RPT, the mean CFU count in the P5C100-treated group 172 includes one footpad with no detectable CFU which was likely due to a non-productive infection. 173
Excluding this footpad, the mean CFU count is 2.98±0.96. After 4 weeks of treatment, swelling 174 grade was reduced to a minimum median of 0.25 and 0.125 in the high-dose R40C100 and 175 P20C100 groups, respectively. In terms of CFU reduction, all treatment groups, except C100, 176 resulted in a statistically significant reduction of CFU, when compared to untreated mice 177 (p=0.030 -0.001). All high-dose RIF-and RPT-containing regimens performed better than 178 standard R10C100 (p=0.001) and no worse than the RS control. Low-dose R5C100 performed 179 less well, especially if 2 footpads with no detectable CFU were excluded as possibly never 180 productively infected (in which case the mean CFU count was 2.64±1.09. Footpads from the 181 R40C100 group and all RPT-containing regimens were culture-negative after 4 weeks of 182 treatment (i.e. no colonies could be observed after plating the undiluted footpad homogenate). 183
The CFU outcome of R10 and R10CLR100 after four weeks of treatment were both 1.77 (± 0.39 184 -0.44). The addition of CLR to R10 thus seemed to have no effect on the outcome in this 185 experiment. 186
187
The previously WHO recommended treatment of R10S150 resulted in the highest healing rate, as 188 evidenced by the finding that 80% of treated animals exhibited a swelling grade of zero upon 189 completion of treatment. The swelling grade was reduced to zero in 60% and 50% of animals 190 receiving R20C100 and P20C100, respectively. There appeared to be no ceiling effect with the doses tested. In contrast, for RPT, no dose-209 response effect was evident at week 2 and the CFU counts were reduced to zero in all groups 210 receiving RPT at week 4 of treatment. It is possible that the pharmacological ceiling was 211 reached. However, this would be surprising given the increasing dose-response relationship up to 212 RPT doses of 160 mg/kg that we previously observed in a mouse model of TB (33). Despite a 213 three-day interval between the last dose of drug and sacrificing animals for microbiological 214 analysis of footpads, we cannot exclude RPT carryover owing to its long half-life and possible 215 elevated tissue concentration (17). antimicrobial therapy (37). We hypothesize that more mice from culture-negative as well as low-230 CFU treatment groups would have progressed to swelling grade 0 during follow-up. 231
232
Integrated approaches to control neglected tropical diseases are increasingly advocated. It is thus 233 noteworthy that high-dose, short-course regimens with rifampicin are being investigated as 234 potential therapeutic agents for lymphatic filariasis and onchocerciasis (38) in addition to TB, 235 offering potential synergies in the research and implementation of new, more efficient regimens 236 in co-endemic areas. 237 13 238
We successfully employed a mouse model of M. ulcerans disease and achieved comparable 239 clinical and microbiological results in the control groups as in previous experiments with the 240 MU1059AL strain (24, 25) . The decline in swelling grade and CFU in untreated mice can be 241 attributed to a transition into a stationary phase about 7-9 weeks post-infection. Although the 242 autoluminescent strain used in this experiment was previously reported to be fully virulent, we 243 cannot exclude the possibility that it is slightly less virulent than its wild-type parent rendering it 244 more prone to spontaneous clearance from the footpads (25). 245
246
In summary, high-dose RIF and RPT in combination with CLR performed well in a mouse 247 model of M. ulcerans disease and warrant further investigation. These regimens can be 248 administered orally; the elevated doses appear safe in humans when administered for 2 months or 249 less (12, 13, 19) . As BU has already been treated with rifampin and clarithromycin for several 250 years, logistics and handling knowledge is already in place with health-care providers and a 251 dose-adjustment could be easily implemented if shown effective in humans. One potential issue 252 is that higher doses of rifamycins are likely to have a greater inductive effect on CLR 253 metabolism in patients and could lead to subtherapeutic CLR exposures. We are currently 254 evaluating other potential companion drugs for high-dose rifamycin regimens and will proceed to 255 test whether they can cure M. ulcerans as short-course regimens in mice and ultimately, human 256 week 2 and week 4, footpads dissected and minced and plated on 7H11 agar for colony counting 436 and CFU analysis. There was a dose dependent reduction in CFU with elevating rifamycin doses. 437
No ceiling effect was observed for R. At week 4, all rifapentine (P) containing regimens were 438 culture negative, as was R40C100. CFU, colony forming unit; R, Rifampin; S, Streptomycin; C, 439 Clarithromycin; P, Rifapentine, numbers after drugs indicate doses in mg/kg.
